Pharmacokinetics and Antitumor Effects of an Interleukin-2 Immunocomplexing Agent in Murine Renal Cell Carcinoma

Mototsugu Oya, Ken Marumo, Masaru Murai, Hiroshi Tazaki

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Conventional therapy for renal cell carcinoma (RCC) using systemic administration of interleukin-2 (IL-2) has shown limited anti-tumor action. The purpose of this study was to investigate the anti-tumor effects of a newly developed immune complex of IL-2 (IC) against RCC. Methods: IC was prepared by mixing IL-2 and an anti-IL-2 monoclonal antibody at a molar ratio of 2:1. The pharmacokinetics and anti-tumor effects of IC were then studied in a murine RCC line, Renca. Results: Serum IL-2 levels were sustained longer in mice given IC than in mice given IL-2 alone after either subcutaneous or intratumoral injections. After an intratumoral injection of IC, the IL-2 concentration in the tumor nodules remained higher compared with mice given IL-2 alone. The anti-tumor effect was most pronounced in mice treated with intratumoral injections of IC. Conclusions: Results obtained here indicate that an immune complex of IL-2 provides a useful tool for the treatment of RCC by altering the pharmacokinetics of IL-2 in vivo.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalInternational Journal of Urology
Volume3
Issue number2
Publication statusPublished - 1996

Fingerprint

Renal Cell Carcinoma
Interleukin-2
Pharmacokinetics
Neoplasms
Antigen-Antibody Complex
Injections
Monoclonal Antibodies
Cell Line
Therapeutics
Serum

Keywords

  • Drug delivery system
  • Immune complex
  • Interleukin-2
  • Monoclonal antibody
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Pharmacokinetics and Antitumor Effects of an Interleukin-2 Immunocomplexing Agent in Murine Renal Cell Carcinoma. / Oya, Mototsugu; Marumo, Ken; Murai, Masaru; Tazaki, Hiroshi.

In: International Journal of Urology, Vol. 3, No. 2, 1996, p. 141-144.

Research output: Contribution to journalArticle

@article{531b3e77ec5c47938045045e125e0a5a,
title = "Pharmacokinetics and Antitumor Effects of an Interleukin-2 Immunocomplexing Agent in Murine Renal Cell Carcinoma",
abstract = "Background: Conventional therapy for renal cell carcinoma (RCC) using systemic administration of interleukin-2 (IL-2) has shown limited anti-tumor action. The purpose of this study was to investigate the anti-tumor effects of a newly developed immune complex of IL-2 (IC) against RCC. Methods: IC was prepared by mixing IL-2 and an anti-IL-2 monoclonal antibody at a molar ratio of 2:1. The pharmacokinetics and anti-tumor effects of IC were then studied in a murine RCC line, Renca. Results: Serum IL-2 levels were sustained longer in mice given IC than in mice given IL-2 alone after either subcutaneous or intratumoral injections. After an intratumoral injection of IC, the IL-2 concentration in the tumor nodules remained higher compared with mice given IL-2 alone. The anti-tumor effect was most pronounced in mice treated with intratumoral injections of IC. Conclusions: Results obtained here indicate that an immune complex of IL-2 provides a useful tool for the treatment of RCC by altering the pharmacokinetics of IL-2 in vivo.",
keywords = "Drug delivery system, Immune complex, Interleukin-2, Monoclonal antibody, Renal cell carcinoma",
author = "Mototsugu Oya and Ken Marumo and Masaru Murai and Hiroshi Tazaki",
year = "1996",
language = "English",
volume = "3",
pages = "141--144",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Pharmacokinetics and Antitumor Effects of an Interleukin-2 Immunocomplexing Agent in Murine Renal Cell Carcinoma

AU - Oya, Mototsugu

AU - Marumo, Ken

AU - Murai, Masaru

AU - Tazaki, Hiroshi

PY - 1996

Y1 - 1996

N2 - Background: Conventional therapy for renal cell carcinoma (RCC) using systemic administration of interleukin-2 (IL-2) has shown limited anti-tumor action. The purpose of this study was to investigate the anti-tumor effects of a newly developed immune complex of IL-2 (IC) against RCC. Methods: IC was prepared by mixing IL-2 and an anti-IL-2 monoclonal antibody at a molar ratio of 2:1. The pharmacokinetics and anti-tumor effects of IC were then studied in a murine RCC line, Renca. Results: Serum IL-2 levels were sustained longer in mice given IC than in mice given IL-2 alone after either subcutaneous or intratumoral injections. After an intratumoral injection of IC, the IL-2 concentration in the tumor nodules remained higher compared with mice given IL-2 alone. The anti-tumor effect was most pronounced in mice treated with intratumoral injections of IC. Conclusions: Results obtained here indicate that an immune complex of IL-2 provides a useful tool for the treatment of RCC by altering the pharmacokinetics of IL-2 in vivo.

AB - Background: Conventional therapy for renal cell carcinoma (RCC) using systemic administration of interleukin-2 (IL-2) has shown limited anti-tumor action. The purpose of this study was to investigate the anti-tumor effects of a newly developed immune complex of IL-2 (IC) against RCC. Methods: IC was prepared by mixing IL-2 and an anti-IL-2 monoclonal antibody at a molar ratio of 2:1. The pharmacokinetics and anti-tumor effects of IC were then studied in a murine RCC line, Renca. Results: Serum IL-2 levels were sustained longer in mice given IC than in mice given IL-2 alone after either subcutaneous or intratumoral injections. After an intratumoral injection of IC, the IL-2 concentration in the tumor nodules remained higher compared with mice given IL-2 alone. The anti-tumor effect was most pronounced in mice treated with intratumoral injections of IC. Conclusions: Results obtained here indicate that an immune complex of IL-2 provides a useful tool for the treatment of RCC by altering the pharmacokinetics of IL-2 in vivo.

KW - Drug delivery system

KW - Immune complex

KW - Interleukin-2

KW - Monoclonal antibody

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0030111345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030111345&partnerID=8YFLogxK

M3 - Article

C2 - 8689509

AN - SCOPUS:0030111345

VL - 3

SP - 141

EP - 144

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 2

ER -